Actively Recruiting

Age: 16Years - 99Years
All Genders
NCT05450783

Tissue and Metabolic Characterization of Arrhythmogenic Cardiomyopathies by Hybrid PET-MRI Imaging, Impact of the Observed Profiles on the Phenotype and on the Evolution of Cardiomyopathy

Led by Nantes University Hospital · Updated on 2026-04-17

80

Participants Needed

5

Research Sites

226 weeks

Total Duration

On this page

Sponsors

N

Nantes University Hospital

Lead Sponsor

U

University Hospital, Brest

Collaborating Sponsor

AI-Summary

What this Trial Is About

Status of the research project: The main complications of arrhythmogenic cardiomyopathies (AC) are sudden death, more rarely heart failure. Recently, data are emerging in favor of an associated role of myocardial inflammation and myocarditis in this pathology, but the impact of inflammation on the presentation and prognosis of the cardiomyopathy, as well as its mechanisms, are not clearly elucidated. To date, endomyocardial biopsy is the gold standard for documenting myocardial inflammation. Aim of the research: To evaluate the interest of a new hybrid PET-MR imaging tool for tissue and metabolic characterization of AC associating MRI and 18F-FDG PET, already used in inflammatory pathologies (cardiac sarcoidosis). Project description: Multicentric observational study of 80 patients with genetic AC undergoing PET-MR. Description of the observed profiles and their impact on the phenotype of the cardiomyopathy and its evolution, study of associated immunological mechanisms, correlation with available anatomopathological data. Expected results and perspectives: first non-invasive description of tissue and metabolic phenotype of AC by PET-MR imaging and its prognostic role, basis for pathophysiological and therapeutic research in case of confirmation of the performances of this imaging for the detection of myocardial inflammation.

CONDITIONS

Official Title

Tissue and Metabolic Characterization of Arrhythmogenic Cardiomyopathies by Hybrid PET-MRI Imaging, Impact of the Observed Profiles on the Phenotype and on the Evolution of Cardiomyopathy

Who Can Participate

Age: 16Years - 99Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Male and female over 16 years old
Not Eligible

You will not qualify if you...

  • Patients and their relatives with left ventricular or biventricular AC carrying pathogenic or likely pathogenic variants in specified genes (PKP2, DSG2, DSC2, JUP, DSP, DES, FLNC, PLN, LMNA, TMEM43, CDH2, BAG3, RYR2, RBM20)
  • Diagnosis of sarcoidosis or any known autoimmune disease
  • History of myocardial infarction
  • Patient under guardianship, curatorship, or safeguard of justice

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 5 locations

1

CHU Angers

Angers, France, 49000

Actively Recruiting

2

CHU Brest

Brest, France, 29000

Actively Recruiting

3

CHU de Nantes

Nantes, France, 44093

Actively Recruiting

4

AP-HP La Salpêtrière

Paris, France, 75013

Actively Recruiting

5

CHU de Rennes

Rennes, France, 35000

Actively Recruiting

Loading map...

Research Team

N

Nicolas Piriou, PH

CONTACT

A

Aurélie Thollet

CONTACT

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here